Vanguard Group
IMRX icon

Vanguard Group’s Immuneering IMRX Stock Holding History

Vanguard Group’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$16.9M Buy
2,568,293
+153,049
+6% +$983K ﹤0.01% 2696
2025
Q3 		$16.9M Buy
2,415,244
+1,358,322
+129% +$7.05M ﹤0.01% 2711
2025
Q2 		$3.56M Hold
1,056,922
– – ﹤0.01% 3321
2025
Q1 		$1.61M Hold
1,056,922
– – ﹤0.01% 3563
2024
Q4 		$2.33M Sell
1,056,922
-13,400
-1% -$27.8K ﹤0.01% 3521
2024
Q3 		$2.67M Hold
1,070,322
– – ﹤0.01% 3468
2024
Q2 		$1.37M Sell
1,070,322
-133,344
-11% -$219K ﹤0.01% 3691
2024
Q1 		$3.48M Buy
1,203,666
+129,851
+12% +$728K ﹤0.01% 3426
2023
Q4 		$7.89M Buy
1,073,815
+29,963
+3% +$200K ﹤0.01% 3078
2023
Q3 		$8.02M Buy
1,043,852
+42,722
+4% +$393K ﹤0.01% 3010
2023
Q2 		$10.2M Buy
1,001,130
+125,162
+14% +$1.2M ﹤0.01% 2933
2023
Q1 		$8.51M Buy
875,968
+38,289
+5% +$217K ﹤0.01% 3021
2022
Q4 		$4.06M Buy
837,679
+19,190
+2% +$170K ﹤0.01% 3399
2022
Q3 		$11.7M Buy
818,489
+77,866
+11% +$618K ﹤0.01% 2875
2022
Q2 		$4.01M Sell
740,623
-71,769
-9% -$383K ﹤0.01% 3493
2022
Q1 		$5.26M Buy
812,392
+498,479
+159% +$4.79M ﹤0.01% 3503
2021
Q4 		$5.08M Sell
313,913
-29,688
-9% -$723K ﹤0.01% 3600
2021
Q3 		$9.12M Buy
+343,601
New +$9.23M ﹤0.01% 3292

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM

Vanguard Group's IMRX Position: Q4 2025 in Review

Vanguard Group increased its Immuneering (IMRX) stake by 6.3% in Q4 2025, buying an estimated $983K and bringing the position to 2,568,293 shares worth $16.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2696.

Vanguard Group first reported a position in IMRX in Q3 2021 and has held it in 18 quarters since. The position peaked at $16.9M in Q3 2025. 86 funds tracked by Wall St. Rank hold IMRX as of Q4 2025.

  • Vanguard Group held 2,568,293 shares of Immuneering worth $16.9M as of Q4 2025.
  • Vanguard Group bought 153,049 Immuneering shares in Q4 2025, an estimated $983K.
  • Immuneering made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2696 holding.
  • Vanguard Group first reported a position in Immuneering in Q3 2021 and has held it in 18 quarters since.
  • Vanguard Group's Immuneering position peaked at $16.9M in Q3 2025.
  • 86 funds tracked by Wall St. Rank held Immuneering as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.